Search results
Sep 30, 2021 · Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring...
Nov 22, 2021 · Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder.
Sep 30, 2021 · Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart.
Sep 30, 2021 · At $180 per share, the acquisition values Acceleron at a 13% premium to its closing share price last Thursday and a roughly 40% premium to where shares were trading a month ago. The companies expect their deal to close sometime in the fourth quarter.
Sep 30, 2021 · The US life sciences group said on Thursday it would acquire US-listed Acceleron for $180 per share in cash in a deal that is expected to close in the fourth quarter. It is the latest in a series...
- Adrienne Klasa
Sep 30, 2021 · Upon the successful completion of the tender offer, Merck’s acquisition subsidiary will be merged into Acceleron, and any remaining shares of common stock of Acceleron will be canceled and converted into the right to receive the same $180 per share price payable in the tender offer.
People also ask
How much does Acceleron cost?
Does Merck buy Acceleron Pharma?
Does Acceleron Pharma Inc (Acceleron) offer to buy or sell shares?
How much cash does Acceleron receive after a tender offer?
Oct 12, 2021 · Upon the successful closing of the tender offer, stockholders of Acceleron will receive $180 in cash for each share of Acceleron common stock validly tendered and not validly withdrawn in the offer, without interest and less any required tax withholding.
